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Summary Recent studies have suggested that insulin-like growth factors (IGFs) and insulin-like growth factor
binding proteins (IGFBPs) may be implicated in the development and progression of breast cancer. Prostate-
specific antigen (PSA), a serine protease, may play a role in the regulation of IGFs' function through cleavage
of IGFBP-3, resulting in release of active IGFs from IGFBP-3. As IGFs, IGFBPs and PSA are all present in
breast cancer, possible associations among these proteins were speculated. In this study, we have measured
PSA, IGF-I, IGF-II, IGFBP-1 and IGFBP-3 in tumour tissue cytosols from 200 women with primary breast
cancer, and have examined relationships between IGFs or IGFBPs and PSA along with other markers,
including p53 protein, steroid hormone receptors (oestrogen and progesterone), cathepsin-D, epidermal growth
factor receptor, Her-2/neu protein, S-phase fraction and DNA ploidy. Correlations or associations between
PSA and IGF-I, IGF-II, IGFBP-1 or IGFBP-3 were not observed. IGF-II was positively correlated with both
IGFBP-3 and IGFBP-1. IGF-I was not associated with either of the two binding proteins, nor with IGF-II.
Both IGF-II and IGFBP-3 were inversely associated with the oestrogen receptor, and IGFBP-3 was also
positively associated with S-phase fraction. Our finding of IGF-II and IGFBP-3 in association with
unfavourable prognostic indicators of breast cancer suggests that IGFs may be involved in the progression of
breast cancer.
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Insulin-like growth factors (IGFs), including IGF-I and
IGF-I1, belong to a family of peptide hormones involved in
the regulation of normal cell growth and differentiation.
IGFs exert their action through binding to two types of
specific receptors, one of which (IGF-I receptor) is a
transmembrane protein with tyrosine kinase activity
(Krywicki and Yee, 1992; Daughaday and Rotwein, 1989).
The binding of IGFs to their receptors is modulated by a
group of soluble proteins called insulin-like growth factor
binding proteins (IGFBPs). Six distinct IGFBPs have been
described so far (IGFBP-1 to IGFBP-6). Since only the free
IGFs are able to interact with their cell surface receptors,
IGFBPs regulate the bioavailability and bioactivity of IGFs
through binding to them (Figueroa and Yee, 1992). IGFBP-
3 may also bind to its own receptor on the cell membrane
and functions independently from the IGFs (Oh et al., 1993;
Valentinis et al., 1995).
Loss of functional IGF-I receptor was shown to be
associated with slow cell growth and prolonged cell cycle.
Moreover, the receptor was found to be involved in cell
transformation and apoptosis (LeRoith et al., 1995; Baserga,
1995). Therefore, it was speculated that IGFs may play a
role in the development and progression of cancer.
Experimental studies have shown that IGFs could act as
mitogens and promote the growth of breast tumour cells
(Arteaga et al., 1992) and that IGFBPs regulate the impact
of IGFs on tumour cells (Figueroa and Yee, 1992). The
presence of IGFs and their binding proteins in breast cancer
cells has been well characterised and their relationships have
been studied in both cultured breast cancer cell lines as well
as breast cancer tissues (Cullen et al., 1992; Yee et al., 1991;
Sheikh et al., 1992; McGuire et al., 1992; Pekonen et al.,
1992; Paik 1992).
Responses of breast cancer cells to tamoxifen treatment
were found to be associated with changes in IGFs and
IGFBPs; it was shown IGF-I levels decreased and IGFBP-3
levels increased in the serum of breast cancer patients after
administration of tamoxifen (Pollak et al., 1990; Lonning et
al., 1992). In animal experiments, tamoxifen was shown to
suppress the expression of the IGF-I gene (Huynh et al.,
1993). The association between tamoxifen treatment and
IGFs or IGFBPs suggests that the production of IGFs or
IGFBPs may be regulated by steroid hormones (Pratt and
Pollak, 1993, 1994; Owens et al., 1993; Winston et al., 1994;
Manni et al., 1994). The presence of the oestrogen receptor
(ER) or the progesterone receptor (PR) has also been found
to be associated with levels of both IGFs and IGFBPs in
breast cancer cell lines and tissues (Figueroa et al., 1993; Yee
et al., 1994).
Prostate-specific antigen (PSA) is a glycoprotein and serine
protease with chymotrypsin-like enzymatic activity. PSA has
been found to be able to cleave IGFBP-3 (Cohen et al.,
1992), suggesting that PSA may regulate the function of IGFs
through the digestion of IGFBP-3 (Cohen et al., 1994;
Kanety et al., 1993). Correlations between PSA and some
IGFBPs have been observed in the serum of prostate cancer
patients (Kanety et al., 1993). PSA, currently used as a
biochemical marker for diagnosis and management of
patients with prostate cancer, was initially thought to be
produced exclusively by the prostate, but recently it has been
found in breast cancer tissue (Diamandis et al., 1994). The
presence of PSA in breast cancer was associated with steroid
hormone receptors, and the breast cancer cell lines could
produce PSA after the cells were stimulated with androgens
or progestins (Yu et al., 1994). Based on these observations,
we speculate that associations may exist among IGFBPs,
IGFs and PSA in breast cancer. In order to investigate this
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possibility, we have analysed 200 breast cancer tissues with
immunoassays for IGF-I, IGF-II, IGFBP-1, IGFBP-3 and
PSA. We have also examined these markers in association
with other prognostic indicators in breast cancer, including
p53 protein, steroid hormone receptors (ER and PR),
cathepsin-D (CATD), epidermal growth factor receptor
(EGFR), Her-2/neu protein (HER-2), S-phase fraction
(SPF) and DNA ploidy. The findings of the study are
reported in this paper.
Materials and methods
Breast cancer specimens and cytosol extraction
Tumour tissue specimens from 200 patients with primary
breast cancer were selected from the tissue bank in the
University of Texas Health Science Center at San Antonio.
The specimens, stored at -80°C until the extraction of tissue
cytosols for this project, were banked after analysis of ER,
PR, SPF and DNA ploidy. Also analysed were other
biochemical markers including EGFR, CATD and HER-2.
Clinical and follow-up information of these patients was not
available.
The cytosolic extracts were prepared in a lysis buffer after
about 200 mg of frozen tissue specimens were pulverised into
a fine powder. The lysis buffer, pH 8.0, contains per litre
50 mmol Tris, 150 mmol sodium chloride, 5 mmol EDTA,
10 g Nonidet NP-40, 100 mg phenylmethylsulphonyl fluoride
(PMSF) and 1 mg each ofaprotinin and leupeptin. The tissue
powder was lysed in 1 ml ofthe lysis buffer for 30 min on ice.
The lysates were then centrifuged at 4°C at 15 000 g for
30 min. The supernatants were assayed for PSA, p53, IGF-I,
IGF-I1, IGFBP-1, IGFBP-3 and total protein.
Measurement of biochemical markers
IGF-I, IGF-II, IGFBP-1 and IGFBP-3 were measured with
immunoassay kits commercially available from Diagnostic
Systems Laboratories (DSL, Webster, TX, USA). The assays
were based on a non-competitive, sandwich-type principle
involving a solid-phase capture antibody and a soluble 25I-
or horseradish peroxidase (HRP)-labelled detection antibody.
All assays were performed according to the manufacturer's
protocols. A brief description of the assays is as follows: The
DSL IGF-I kit is a one-step enzyme-linked immunosorbent
assay (ELISA), involving anti-IGF-I antibody-coated micro-
titration wells and a monoclonal anti-IGF-I detection
antibody labelled with HRP. The IGF-I kit has a standard
range of0.1-6 ,g 11 and a precision of <10% coefficient of
variation (CV).
The DSL IGF-II kit is a two-step immunoradiometric
assay (IRMA), involving anti-IGF-II antibody-coated tubes
and a radioiodinated monoclonal detection antibody. The
IRMA assay has a standard range between 3 and 50 ,ug 1`.
The assay's precision is < 10% CV. Both IGF-I and IGF-I1
assays require an acid-ethanol extraction step which is
designed to dissociate and remove IGFBPs from the samples
before analysis. The extraction procedures include sequential
mixture of 50 jil sample with 450 ,ul extraction solution at
room temperature for 30 min, centrifugation of the mixture
at 10 000 r.p.m. for 3 min, mixture of the supernatant at 1:1
ratio with neutralisation solution, and assay of the final
mixture diluted (1:5) in an assay buffer (a final dilution of
sample 1:100).
The DSL IGFBP-1 and IGFBP-3 kits are also based on
ELISA principles. The assays were performed in microtitra-
tion wells coated with a highly specific anti-IGFBP-1 or
IGFBP-3 antibody. The IGFBP-3 ELISA kit uses a
polyclonal detection antibody, while a monoclonal antibody
is used in the IGFBP-l kit. Both assays are based on a two-
step assay principle and incorporate HRP as label. The
calibrator ranges are between 0.25 and 25 ug 1-1 for the
IGFBP-1 kit and between 2 and 100 jug 1 1 for the IGFBP-3
kit. The precision is < 10% CV for both assays.
The methods used for the measurement of ER, PR,
EGFR, CATD, HER-2, SPF, DNA ploidy, p53, PSA and
total protein have been described previously (Levesque et al.,
1995). Briefly, ER and PR were measured by the dextran-
coated charcoal method. EGFR was determined by a
radiolabelled ligand-binding assay. An EIA kit from Triton
Diagnostics was used to measure CATD, and HER-2 was
measured by the Western blotting technique. DNA flow
cytometry was used to determine DNA content and S-phase
fraction, which was defined as the percentage of cells in S
phase among the diploid populations. Based on the previous
study, less than 6.7% of S-phase fraction was considered a
cut-off for favourable prognosis. PSA and p53 were measured
by two in-house sandwich-type time-resolved immunofluoro-
metric assays. For the samples which were used for the
measurements of ER, PR, EGFR, CATD and HER-2, the
total protein was determined by the Lowry method, and for
those used for PSA and p53 measurement, the protein was
measured by a bicinchoninic acid-based commercial kit from
Pierce.
The measurements of ER, PR, EGFR, CATD, HER-2,
SPF and DNA ploidy were performed in San Antonio when
the specimens were collected, whereas PSA, p53, IGFs and
IGFBPs were determined later in Toronto when the present
study was undertaken.
Statistical analysis
As most of the data generated by the immunoassays or other
analytical methods do not follow Gaussian distributions, the
numerical values were analysed non-parametrically. The
Spearman correlation coefficients were calculated for asses-
sing the correlation between any two of the markers, and the
Wilcoxon rank sum test was employed to compare the
median concentrations between groups. The numerical data
were also classified into categories, and were analysed using
chi-square or Fisher's exact tests. The cut-off values for the
categorical group were either based on the percentile
boundary (median) or were established elsewhere (Levesque
et al., 1995). For IGFs and IGFBPs, the values were grouped
into high and low categories based on the medians. PSA and
p53 were classified into positive and negative groups using
cut-off levels of 0.03 ng mg-' and 5 units g-1 respectively.
Positive and negative classifications were also used for ER
(3 fmol mg-1), PR (5 fmol mg-1), EGFR (10 fmol mg-') and
CATD (51 pmol mg-1). HER-2 was categorised into high
and low groups following the method described by Tandon et
al. (1989).
Results
Because of the lack of enough sample volume in some
specimens, of the 200 samples, 135 were measured for IGF-I
and IGF-II, 160 were measured for IGFBP-1, and 169 were
measured for IGFBP-3. The frequency distributions of the
values of IGFs and IGFBPs are shown in Figures 1-4. The
numerical distributions of the four markers are demonstrated
in Table I. For IGF-I, the lowest value was 0.9 ng mg-1 and
the highest 52 ng mg-'. The median and mean were close, 7
and 8 ng mg- respectively. In comparison to IGF-I, the IGF-
II levels were much higher, ranging from 4.2 to 72 ng mg-'
with an identical median and mean value of 36 ng mg- . With
regard to the two binding proteins, IGFBP-3 concentration
was much higher than IGFBP-1. The values ranged from 0.02
to 6.6 ng mg-1 for IGFBP-1 and from 0.2 to 369 ng mg-' for
IGFBP-3. The median values were all lower than the means
for the two markers, suggesting a positive skew of the data
from the normal distribution (Table I).
The correlations between any two of these markers are
shown in Table II. Among the two IGFs and two IGFBPs,
the levels ofIGFBP-3 were positively correlated with IGFBP-
1 (r=0.20, P=0.02) and IGF-II (r=0.38, P<0.01), but not
with IGF-I (r=0.10, P=0.27). IGFBP-1 was not correlatedIGFs and IGFBPs in breast cancer 9 H Yu et at
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Figure 2 Frequency distribution of IGF-II.
with either of the IGFs (r= -0.08, P=0.36 for IGF-I;
r=0.05, P=0.54 for IGF-II). The two IGFs did not correlate
to each other (r=0.08, P=0.35).
PSA levels were not correlated with any of the four
markers, IGF-I (r= -0.03, P=0.72), IGF-II (r= -0.12,
P=0.17), IGFBP-1 (r= -0.01, P=0.85) or IGFBP-3
(r= -0.03, P=0.72). An inverse correlation was seen
between ER and IGF-II (r= -0.19, P=0.03) or IGFBP-3
(r= -0.31, P<0.01), and a similar correlation was also
suggested between PR and IGFBP-3 (r= -0.16, P=0.04).
IGF-II was positively correlated with p53 (r= 0.27, P<0.01),
and was negatively correlated with CATD (r= -0.19,
P=0.02). IGFBP-3 was positively correlated with EGFR
(r=0.17, P=0.03) and SPF (r=0.27, P<0.01). Most of the
correlations were relatively weak; their correlation coefficients
were less than 0.3.
Tables III and IV demonstrate the associations between
any two of the markers studied when their values were
classified into two groups. IGFs and IGFBPs were grouped
into high and low categories based on their median values.
Other markers were classified either into positive vs negative
groups or into high and low categories based on specific cut-
off levels. The results of this analysis were quite similar to
those of the correlation analysis for the relationships between
Table I Distribution of IGF-I, IGF-II, IGFBP-1 and IGFBP-3
levels in breast cancer cytosols
Percentile (ng mg-J)a
Marker 0% 25% 50% 75% 100% Mean
IGF-I 0.9 5.3 7.0 9.5 52 8.0
IGF-II 4.2 29 36 41 72 36
IGFBP-1 0.02 0.15 0.32 0.62 6.6 0.51
IGFBP-3 0.2 44 63 95 369 81
aValues are in ng ofmarker per mg oftotal protein in the cytosolic
extract.
Table II Spearman correlation analysis
markers
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Figure 3 Frequency distribution of IGFBP-1.
between the prognostic
Marker IGF-I IGF-II IGFBP-1 IGFBP-3
PSA
,a -0.03 -0.12 -0.01 -0.03
P-value 0.72 0.17 0.85 0.72
ER
r -0.15 -0.19 0.08 -0.31
P-value 0.09 0.03 0.30 <0.01
PR
r 0.01 -0.10 0.11 -0.16
P-value 0.89 0.23 0.17 0.04
p53
r -0.02 0.27 -0.08 0.06
P-value 0.84 <0.01 0.33 0.43
CATDb
r -0.16 -0.19 0.15 0.01
P-value 0.06 0.02 0.06 0.91
EGFRC
r -0.05 -0.03 -0.01 0.17
P-value 0.54 0.73 0.90 0.03
SPFd
r 0.004 0.14 -0.03 0.27
P-value 0.96 0.10 0.72 <0.01
IGFBP-3
r 0.10 0.38 0.20
P-value 0.27 <0.01 0.02
IGFBP-1
r -0.08 0.05
P-value 0.36 0.54
IGF-II
r 0.08
P-value 0.35
ar, Spearman correlation coefficient; bCATD, cathepsin D;CEGFR,
epidermal growth factor receptor dSPF, S-phase fraction.
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Table III Associations between prognostic markers and IGFs
Marker IGF-I IGF-II
(Oo) Total Higha Lowb Higha Lowb
PSA (+) 25.2 27.1 23.1 27.1 23.1
P-value 0.59 0.59
ER (+) 83.7 82.9 84.6 77.1 90.8
P-value 0.78 0.03
PR (+) 61.5 64.3 58.5 54.3 69.2
P-value 0.49 0.08
p53 (+) 23.7 22.9 24.6 25.7 21.5
P-value 0.81 0.57
CATD (+) 31.9 22.9 41.5 24.3 40.0
P-value 0.02 0.05
EGFR (+) 24.4 24.3 24.6 25.7 23.1
P-value 0.96 0.72
HER2 (+) 22.2 20.0 24.6 21.4 23.1
P-value 0.52 0.82
SPF >6.7% 37.0 35.7 38.5 40.0 33.9
P-value 0.74 0.46
Diploid 45.9 50.0 41.5 40.0 52.3
P-value 0.32 0.15
IGFBP-1 (+) 48.5 45.7 51.7 47.8 49.2
P-value 0.50 0.87
IGFBP-3 (+) 52.6 56.5 48.4 68.6 34.9
P-value 0.35 <0.01
aHigh: IGF values higher than or equal to the median level. bLow:
IGF values lower than the median level.
Table IV Associations between prognostic markers and IGFBPs
Marker IGFBP-I IGFBP-II
(%) Total Higha Lowb Higha Low"
PSA (+) 26.3 24.1 28.4 26.7 30.1
P-value 0.53 0.63
ER (+) 85.6 81.0 90.1 77.9 92.8
P-value 0.10 0.01
PR (+) 61.9 63.3 60.5 54.7 68.7
P-value 0.72 - 0.06
p53 (+) 21.9 20.3 23.5 26.7 18.1
P-value 0.62 0.18
CATD (+) 34.4 40.5 28.4 36.1 32.5
P-value 0.11 0.63
EGFR (+) 23.1 21.5 24.7 25.6 22.9
P-value 0.63 0.68
HER2 (+) 20.0 21.5 18.5 22.1 16.9
P-value 0.64 0.39
SPF >6.7% 36.3 43.0 29.6 47.7 24.1
P-value 0.08 <0.01
Diploid 47.5 41.8 53.1 39.5 51.8
P-value 0.15 0.11
aHigh: IGF values higher than or equal to the median level. bLow:
IGF values lower than the median level.
IGFs and IGFBPs or between IGFs or IGFBPs and PSA,
ER, CATD or SPF. However, unlike the results of the
correlation analysis, a positive association between p53 and
IGF-II was not found, nor was an association of IGFBP-3
with EGFR observed.
IGF-II was positively associated with IGFBP-3 (69% of
high-level IGFBP-3 in high IGF-I group vs 35% in low IGF-
II group, P<0.01). PSA positivity did not show any
association with either of the IGFs (27% in high and 23%
in low IGFs, P= 0.59) or either of the IGFBPs (24% or 27%
in high and 28% or 30% in low IGFBPs, P=0.53 or 0.63).
ER status was inversely associated with IGF-Il (77% of ER
positivity in high IGF-II group vs 91% in low IGF-II group,
P=0.03) or with IGFBP-3 (78% and 93% of ER positivity in
high and low IGFBP-3 respectively, P=0.01). A similar but
weak association between PR and IGFBP-3 was also
observed (55% vs 69%, P=0.06). An inverse association
was suggested between CATD and both IGFs (23% or 24%
of high-level CATD in high IGFs vs 42% or 40% in low
IGFs, P=0.02 or 0.05). SPF was positively associated with
IGFBP-3 (48% of SPF in high vs 24% in low IGFBP-3,
P<0.01).
DNA ploidy, p53 and HER-2 protein did not show any
association with either IGFs or IGFBPs. The results of the
Wilcoxon rank sum test which compared the median values
of IGFs or IGFBPs between two categories of another
marker, such as PSA-positive vs PSA-negative groups, were
similar to those of chi-square tests (data not shown).
Discussion
Given the fact that IGFs bind to other proteins in serum or
cells, an extraction step which separates the IGFs from their
binding proteins has been included in the procedure of IGF
measurement. The acid -ethanol method is used for the
extraction. The efficiency of the extraction has been evaluated
by comparing the IGF values in 20 serum samples extracted
by the acid-ethanol method with those extracted by acid gel
filtration chromatography, a method regarded as a standard
for extraction. IGF levels in the samples extracted by the two
methods were highly correlated to each other (r=0.98)
(Khosravi et al., 1996).
Among the two IGFs and two IGFBPs, IGF-II and
IGFBP-3 were shown to have a strong positive correlation;
the Spearman correlation coefficient was 0.38 (P<0.01).
IGFBP-1 was also significantly correlated with IGFBP-3
(r=0.20; P=0.02). No correlation was found between the
two IGFs. IGF-I did not correlate to either ofthe IGFBPs. A
positive correlation between IGF-II and IGFBP-3 was also
suggested in a study which found that the mRNA levels of
IGF-II and IGFBP-3 declined after the reduction of
oestrogen level, and were elevated again when the oestrogen
level increased (Manni et al., 1994).
PSA digestion of IGFBP-3 has been observed previously
in seminal plasma (Cohen et al., 1992). Experimental study
showed that this digestion could result in recovery of the
mitogenic effect of IGFs on prostatic cells, which was
believed to be suppressed by IGFBP-3 (Cohen et al., 1994).
An inverse correlation between IGFBP-3 and PSA was also
observed in the serum of prostate cancer patients (Kanety et
al., 1993). More recently, it was found that IGF-I was able to
activate the androgen receptor directly (Culig et al., 1994).
Androgen, the legitimate ligand of androgen receptor, is
known to up-regulate the transcription of PSA mRNA
(Young et al., 1991). PSA was initially thought to be
produced specifically by the prostate, but our recent studies
demonstrated the presence of PSA in breast cancer tissue
(Diamandis et al., 1994). If PSA was a protease of IGFBP-3
in breast tissue, a correlation or association between PSA and
IGFBP-3 might be expected. However, such a relationship
was not observed in this study. This may suggest that the
cleavage of IGFBP-3 by PSA does not occur in breast cancer
or that PSA in the breast is not enzymatically active.
Other explanations for our finding of no association
between PSA and IGFBP-3 in breast cancer may also exist.
One of the possibilities could be the method we used to
measure IGFBP-3. It is known that IGFBP-3 is present in the
circulation or tissues in two major molecular forms, intact
IGFBP-3 and IGFBP-3 fragments (Gargosky et al., 1992).
The fragments are the products ofproteolytic cleavage by the
proteases of IGFBP-3. The total amount of IGFBP-3 (intact
plus fragments) may remain the same after the proteolytic
process, while the ratio of the intact IGFBP-3 and its
fragments undergoes substantial changes. Our method for
IGFBP-3 is a sandwich-type immunoassay which quantifies
both intact IGFBP-3 and IGFBP-3 fragments. The method
1245ad m iPs -I cmer
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used by others for prostate cancer study (Kanety et al., 1993)
was a ligand-binding assay, which detected only the intact
IGFBP-3, as the binding affinity of IGFBP-3 to its ligand
IGFs is dependent on the complete structure of IGFBP-3.
Fragmented IGFBP-3 loses its ligand-binding ability. There-
fore, the levels of IGFBP-3 measured by the ligand-binding
method should be lower than those measured by our method,
and the two measurements may suggest different status of the
protein and its relationships with other substances. It would
provide additional information if the two types of methods
could have been compared in this study.
Since both PSA and IGFs along with their binding
proteins are associated with steroid hormone regulation, it
was speculated that associations between PSA and IGFBPs
or IGFs might be present only in the subgroups of patients
who were positive for the steroid hormone receptors. Based
on this speculation, we further examined the association
between PSA and IGFBPs or IGFs within a subgroup of
tumours which were either ER positive or negative. However,
the results rmained the same as those without the
adjustment for steroid hormone receptor.
The presence of ER or PR in breast cancer is known to
relate to a good prognosis of breast cancer patients, whereas
high levels of p53 protein, CATD, EGFR or HER-2 protein
are thought to be associated with unfavourable outcome of
the disease (McGuire et al., 1990; McGuire and Clark, 1992).
High percentage of SPF or aneuploid DNA is also believed
to be indicative of poor prognosis. With regard to PSA, it
was recently found by our group that the presence of PSA
could suggest a favourable outcome of breast cancer (Yu et
al., 1995). Combining all the findings in the study, we
observed that high levels of IGF-H and IGFBP-3 tended to
be related to unfavourable prognostic indicators of breast
cancer. It included an inverse correlation as well as
association between ER and IGF-II or IGFBP-3, and a
positive correlation and association between IGFBP-3 and
SPF. There was also a positive correlation but not a positive
association between IGF-H and p53 and between IGFBP-3
and EGFR.
Under the overall trend of IGFs and IGFBPs in
association with poor prognostic markers of breast cancer,
CATD was the only exception. CATD was shown in the
study to have an inverse correlation as well as association
with both IGF-II and IGF-I. However, many studies have
demonstrated that CATD is an indicator for poor prognosis.
We were unable to find a reasonable explanation for this
observation.
Our finding of IGF-II and IGFBP-3 in association with
poor prognostic markers of breast cancer is consistent with
the findings demonstrated by others. An inverse relationship
between ER and IGFBP-3 has been reported in a number of
studies (Yee et al., 1991; Manni et al., 1994; Figueroa et al.,
1993; Clemmons et al., 1990). Cell culture studies demon-
strated that IGFs as mitogens could facilitate the growth of
tumour cells and increase the resistance of cells to apoptosis
(Baserga, 1995). IGF levels were reduced in patients who
responded well to tamoxifen treatment (Pollak et al., 1992).
Since IGFBP-1 and -3 are not the only binding proteins
present in breast cancer cells, the real relationships between
IGFs and IGFBPs and between IGF axis and other proteins
will not be fully understood until all other binding proteins
(i.e. IGFBP-2, -4, -5 and -6) are under investigation. Further
studies that investigate both IGFs and all the binding
proteins are needed.
Studies on tumour tissue cytosols inherit a potential
limitation, which is the homogeneity of the tissue specamen.
Tumour tissues from different patients may contain different
amounts of tumour cells and other tissues, such as connective
tissues and blood vessels. This variation may in turn result in
variations in our measurement ofvarious protein markers. In
order to control for this variation, we measured the tumour
cell content in each tissue specimen by cytometry. About
72% of tissue samples contained more than 50% tumour
cells, and 26% samples had tumour cell content between 20%
and 50%. Only 2% of specimens had tumour cell content
between 10% and 20%. The variation of tumour cell volume
among these samples is relatively limited. A substantial
impact of tissue homogeneity on our observations should not
be expected.
It remains unknown if the measurement of IGFs and
IGFBPs in the serum or tissue extracts of breast cancer
patients will have any clinical implication. A recent study
examined the levels of IGFBPs in tumour cytosols in
association with the survival of patients with node-negative
breast cancer. It was found that patients with low levels of
IGFBP-4 in their tumour had longer disease-free survival,
and this association was seen only in patients with large
tumours. Other IGFBPs did not show any relationship with
survival (Yee et al., 1994). Unfortunately, we could not
examine the relationship between IGFs or IGFBPs and
patient survival in this study since the follow-up information
of these patients was not available.
In summary, IGF-I, IGF-II, IGFBP-1 and IGFBP-3 levels
were measured in breast cancer tissue with immunoassays. A
positive correlation was seen between IGF-H and IGFBP-3.
IGFBP-1 was also weakly associated with IGFBP-3, but was
not associated with either of the IGFs. IGF-I was associated
with neither of the binding proteins, nor with IGF-II. High
levels of IGF-ll and IGFBP-3 tended to be related to
unfavourable prognostic markers of the cancer, such as high-
level SFP or ER negative status. Correlations or associations
between PSA and IGFBPs or IGFs were not observed. As
suggested in other studies, IGF-H and IGFBP-3 seem to be
involved in the development and/or progression of breast
cancer. Studies to clarify further their role in breast cancer
are needed.
Abb
IGFs, insulin-like growth factors; IGFBPs, insulin-like growth
factor binding proteins; IGF-I, insulin-like growth factor I; IGF-
II, insulin-like growth factor II; IGFBP-1, insulin-like growth
factor binding protein 1; IGFBP-3, insulin-like growth factor
binding protein 3; PSA, prostate-specific antigen; ER, oestrogen
receptor, PR, progesterone receptor, CATD, cathepsin D; EGFR,
epidermal growth factor receptor; HER-2, Her-2/neu protein; SPF,
S-phase fraction; HRP, horseradish peroxidase; ELISA, enzyme-
linked immunosorbent assay; IRMA, immunoradiometric assay.
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